O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
(+6.3%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18
Avg Time Held Equity + Options
2.2
years
Top 10 Avg Time Held Equity + Options
1.9
years
Top 20 Avg Time Held Equity + Options
1.8
years
Avg Time Held Equity only
2.4
years
Top 10 Avg Time Held Equity only
1.9
years
Top 20 Avg Time Held Equity only
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$52.4M |
| 2 |
Cigna
CI
|
+$48.2M |
| 3 |
United Therapeutics
UTHR
|
+$38.6M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$29.4M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$105M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$93.6M |
| 3 |
Tenet Healthcare
THC
|
+$81.8M |
| 4 |
Boston Scientific
BSX
|
+$39.8M |
| 5 |
Cytokinetics
CYTK
|
+$35.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.63% |
| 2 | Miscellaneous | 2.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Alto Neuroscience
ANRO
$852M
| $1M | 0.02% |
250,000
| – | – |
2024 Q4
3 quarters
|
|
102
Lyell Immunopharma
LYEL
$195M
| $840K | 0.02% |
51,727
| – | – |
2025 Q2
1 quarter
|
|
103
DELISTED
Kezar Life Sciences
KZR
| $752K | 0.02% |
192,700
| – | – |
2022 Q2
13 quarters
|
|
104
Xeris Biopharma Holdings
XERS
$1.78B
| $655K | 0.02% |
80,420
| – | – |
2024 Q1
6 quarters
|
|
105
Passage Bio
PASG
$11.7M
| $474K | 0.01% |
59,046
-243,719
| -80% | -$1.7M |
2020 Q1
22 quarters
|
|
106
DELISTED
DIH Holdings US
DHAI
| $358K | 0.01% |
76,600
| – | – |
2025 Q1
2 quarters
|
|
107
CALL
VistaGen Therapeutics
VTGN
$9.25M
| $160K | ﹤0.01% |
+45,200
| New | +$135K |
2025 Q3
0 quarters
|
|
108
AbCellera Biologics
ABCL
$4.01B
| – | – |
-3,344,568
| Closed | -$11.5M | – |
|
109
Agios Pharmaceuticals
AGIO
$1.85B
| – | – |
-557,900
| Closed | -$18.6M | – |
|
110
CALL
CG Oncology
CGON
$5.49B
| – | – |
-150,000
| Closed | -$3.9M | – |
|
111
Chemomab Therapeutics
CMMB
$9.38M
| – | – |
-235,248
| Closed | -$1.09M | – |
|
112
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-416,900
| Closed | -$9.05M | – |
|
|
113
Cytokinetics
CYTK
$8.82B
| – | – |
-1,077,000
| Closed | -$35.6M | – |
|
114
enGene Therapeutics
ENGN
$105M
| – | – |
-677,977
| Closed | -$2.47M | – |
|
115
PUT
INmune Bio
INMB
$44.7M
| – | – |
-50,000
| Closed | -$116K | – |
|
116
DELISTED
iTeos Therapeutics
ITOS
| – | – |
-700,000
| Closed | -$6.98M | – |
|
|
117
Tenet Healthcare
THC
$21.9B
| – | – |
-465,000
| Closed | -$81.8M | – |
|
118
DELISTED
Third Harmonic Bio
THRD
| – | – |
-5,779,071
| Closed | -$31.4M | – |
|
119
DELISTED
Turnstone Biologics
TSBX
| – | – |
-3,099,265
| Closed | -$1.11M | – |
|
120
Tyra Biosciences
TYRA
$1.29B
| – | – |
-804,603
| Closed | -$7.7M | – |
|
|
121
CALL
UnitedHealth
UNH
$355B
| – | – |
-50,000
| Closed | -$15.6M | – |
|
|
122
UnitedHealth
UNH
$355B
| – | – |
-336,300
| Closed | -$105M | – |
|
|
123
Vertex Pharmaceuticals
VRTX
$127B
| – | – |
-210,287
| Closed | -$93.6M | – |
|
124
Zai Lab
ZLAB
$2.52B
| – | – |
-231,000
| Closed | -$8.08M | – |
|
|
LSB
125
DELISTED
LakeShore Biopharma
LSB
| – | – |
-54,799
| Closed | -$55.9K | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q3 2025 Portfolio in Review
As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.
- OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
- OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
- OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
- OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
- OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
- OrbiMed opened 24 new positions and closed 18 in Q3 2025.
- OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.
Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.